Proximity-Driven Precision: MINT Platform-Powered Discovery and Preclinical Validation of IDP-001, a First-in-Class Bispecific ADC Targeting EGFR
- Exploring MINT™, a membrane interactomics platform that maps cell surface protein microenvironments using proximity proteomics and machine learning to uncover novel, co-localized target pairs for precision therapeutics
- Applying MINT, we identified a tumor-associated proximity antigen (TAPA) to EGFR, enabling a rational bispecific strategy that improves tumor selectivity and minimizes off-target toxicity
- IDP-001, a bispecific ADC targeting EGFR, demonstrates potent and selective antitumor activity in preclinical models, validating the power of proximity-guided discovery to unlock first-in-class therapeutics